Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07472413 · ClinicalTrials.gov registry record · Phase 3
Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project
A Phase 3 study, sponsored by University of Miami.
- Not yet
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT07472413 is a Phase 3 study that has not yet begun recruiting, run by University of Miami. The registered enrollment target is 60 participants.
The verdict
NCT07472413, a Phase 3 study, has not yet begun recruiting, sponsored by University of Miami.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.
Interventions
- DRUG Diphenhydramine
- DRUG Cetirizine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07472413
The ClinicalTrials.gov registry entry for NCT07472413 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Diphenhydramine is the first listed.
NCT07472413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07472413 about?
NCT07472413 is a clinical study titled "Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project". The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versu...
What is the current status of trial NCT07472413?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2026-07-01. Estimated completion is 2028-07-01.
What interventions are being tested in trial NCT07472413?
The interventions under investigation include: Diphenhydramine (DRUG), Cetirizine (DRUG).
Who is sponsoring clinical trial NCT07472413?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.